The present disclosure generally relates to the use of des-aspartate-angiotensin I and/or its derivatives in medicine. In particular, the present disclosure relates to the use of des-aspartate-angiotensin I and/or its derivatives that are its metabolites for the treatment and/or prophylaxis of inflammatory diseases or pathologies, for inducing anti-inflammatory actions and/or reducing inflammation, and/or for treatment of inflammation-related conditions. Specifically, the disclosure relates to the treatment of a malignant growth, an invasive growth, a tumor, a tumor metastasis, a cancer or combinations thereof and to modulate the level or effect of HSP90 or other inflammation-linked molecules in relevant tissue or blood.